BIIB News and Press, Biogen Inc. From 12/19/23

CAMBRIDGE, Mass., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the European Commission has revoked the centralized marketing authorizations for generic versions of Biogen’s product TECFIDERA® (dimethyl fumarate) held by Accord, Mylan, Neur...

2023-12-15 12:26:05 ET More on Biogen Biogen: LEQEMBI's $10 Billion Potential Biogen Inc. (BIIB) Evercore ISI 6th Annual HealthCONx Conference (Transcript) Biogen's Uncertain Strategic Pivots Amidst MS Market Challenges Biogen, Eisai to launch new Alzheimer t...

Friedreich’s ataxia is a genetic, debilitating and life-shortening neuromuscular disease 1 Milestone highlights Biogen’s growing portfolio in rare diseases and focus on addressing unmet needs of patients living with neuromuscular diseases CAMBRIDGE, Mass., Dec. 15, 202...

2023-12-14 13:38:30 ET More on Sage Therapeutics Sage Therapeutics: Postpartum Pioneer Or Fiscal Folly, Zurzuvae Dilemma SAGE Therapeutics, Inc. (SAGE) Q3 2023 Earnings Call Transcript Sage Therapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation Sag...

ZURZUVAE, the first and only oral, once-daily, 14-day treatment course, has shown to provide rapid improvements in depressive symptoms at Day 15 and as early as Day 3 for women with PPD Patient support program, ZURZUVAE For You, and financial assistance available to eligible women with PPD pr...

2023-12-13 12:02:48 ET More on Biogen, Eisai, etc. Biogen: LEQEMBI's $10 Billion Potential Biogen Inc. (BIIB) Evercore ISI 6th Annual HealthCONx Conference (Transcript) Eisai Co., Ltd. 2023 Q2 - Results - Earnings Call Presentation Merck Keytruda combo fails ...

2023-12-12 08:25:49 ET Summary Corvus Pharmaceuticals is a clinical-stage company with potential investment opportunities and a focus on the ITK inhibitor soquelitinib. The company is targeting relapsed peripheral T-cell lymphoma with plans to begin a Phase 3 clinical trial early ...

2023-12-12 03:49:29 ET Summary Today, we take a deeper look at Denali Therapeutics, a biotech company focused on developing treatments for neurodegenerative and lysosomal storage diseases. Denali's developmental focus has drawn several collaboration partnerships from much larger d...

2023-12-09 13:52:00 ET One famous investing maxim advises to buy low and sell high. That's sage advice, but not all stocks are worth investing in while they are down. If they don't go up, you won't have profited from the advice. Take, for instance, Aurora Cannabis (NASDAQ: ACB) ...

2023-12-07 15:13:39 ET More on Biogen Biogen: LEQEMBI's $10 Billion Potential Biogen Inc. (BIIB) Evercore ISI 6th Annual HealthCONx Conference (Transcript) Biogen's Uncertain Strategic Pivots Amidst MS Market Challenges Ionis says Angelman syndrome drug well ...